OncoTrack – shifting the theranostic paradigm. In the course of the OncoTrack program, a comprehensive and systematic molecular interrogation of the primary tumor, metastases and paired healthy tissue, comprising whole genome, exome, transcriptome, methylome, and global proteomes of colon cancer patients is carried out. In tandem, serum and plasma is collected to aid biomarker detection to support prediction of clinical outcomes. To gain insight into the response of individual tumors to drugs, 3D cell cultures of tumors and mouse xenograft models are used, supported by corresponding omics analysis (transcriptomes, proteomes, and ideally, exomes and methylomes are analyzed before and during treatments), to facilitate prediction of patient response and development of drug resistance. Resultant data from individual tumors and patients is used to seed the ModCell™ integrative systems biology predictive platform [84, 85] to focus therapeutic strategies and identify biomarkers for stratification and management of patients. In turn, computer model predictions and experimental models are used to predict tumor responders and non-responders and ultimately identify biomarkers to direct therapeutic strategy.